Targetable biomarkers of NSCLC brain metastases (NSCLC-BM) and primary NSCLC (pNSCLC).
| Biomarkers . | NSCLC-BM (n = 3035) . | n . | pNSCLC (n = 7277) . | n . | P-value . |
|---|---|---|---|---|---|
| ALK fusions | 2.7% | 83 | 1.7% | 123 | .020 |
| ROS1 fusions | 0.3% | 10 | 0.5% | 34 | 1 |
| EGFR mutations | 10.9% | 331 | 12.8% | 929 | .191 |
| Exon19del | 4.5% | 137 | 5.5% | 399 | 1 |
| L858R | 3.2% | 97 | 4.2% | 305 | .435 |
| T790M | 0.6% | 18 | 0.9% | 69 | 1 |
| BRAF mutations | 4.3% | 131 | 4.4% | 318 | 1 |
| V600E | 0.9% | 26 | 1.3% | 92 | 1 |
| NTRK fusions | 0.1% | 4 | 0.1% | 6 | 1 |
| METex14 skipping mutations | 1.0% | 31 | 2.3% | 169 | 1.1E−04 |
| RET rearrangements | 0.5% | 16 | 0.7% | 48 | 1 |
| KRAS mutations | 35.7% | 1082 | 29.6% | 2153 | 4.3E−08 |
| G12C | 15.2% | 460 | 11.7% | 853 | 5.9E−05 |
| ERBB2 mutations | 1.9% | 59 | 1.5% | 107 | 1 |
| MET amplifications | 4.4% | 133 | 2.3% | 170 | 1.4E−06 |
| ICPI biomarkers | |||||
| TMB-High | 55.4% | 1680 | 33.6% | 2442 | 1.3E−91 |
| MSI-H | 0.7% | 22 | 0.3% | 22 | .100 |
| CD274 amplifications | 1.5% | 47 | 1.1% | 81 | 1 |
| STK11 mutations | 17.7% | 538 | 11.6% | 847 | 1.5E−14 |
| KEAP1 mutations | 8.9% | 271 | 5.3% | 388 | 8.5E−10 |
| MDM2 amplifications | 3.3% | 100 | 4.5% | 326 | .128 |
| MDM4 amplifications | 0.8% | 24 | 0.4% | 30 | .540 |
| APOBEC mutational signature | 6.0% | 182 | 3.9% | 286 | 1.7E−04 |
| Biomarkers . | NSCLC-BM (n = 3035) . | n . | pNSCLC (n = 7277) . | n . | P-value . |
|---|---|---|---|---|---|
| ALK fusions | 2.7% | 83 | 1.7% | 123 | .020 |
| ROS1 fusions | 0.3% | 10 | 0.5% | 34 | 1 |
| EGFR mutations | 10.9% | 331 | 12.8% | 929 | .191 |
| Exon19del | 4.5% | 137 | 5.5% | 399 | 1 |
| L858R | 3.2% | 97 | 4.2% | 305 | .435 |
| T790M | 0.6% | 18 | 0.9% | 69 | 1 |
| BRAF mutations | 4.3% | 131 | 4.4% | 318 | 1 |
| V600E | 0.9% | 26 | 1.3% | 92 | 1 |
| NTRK fusions | 0.1% | 4 | 0.1% | 6 | 1 |
| METex14 skipping mutations | 1.0% | 31 | 2.3% | 169 | 1.1E−04 |
| RET rearrangements | 0.5% | 16 | 0.7% | 48 | 1 |
| KRAS mutations | 35.7% | 1082 | 29.6% | 2153 | 4.3E−08 |
| G12C | 15.2% | 460 | 11.7% | 853 | 5.9E−05 |
| ERBB2 mutations | 1.9% | 59 | 1.5% | 107 | 1 |
| MET amplifications | 4.4% | 133 | 2.3% | 170 | 1.4E−06 |
| ICPI biomarkers | |||||
| TMB-High | 55.4% | 1680 | 33.6% | 2442 | 1.3E−91 |
| MSI-H | 0.7% | 22 | 0.3% | 22 | .100 |
| CD274 amplifications | 1.5% | 47 | 1.1% | 81 | 1 |
| STK11 mutations | 17.7% | 538 | 11.6% | 847 | 1.5E−14 |
| KEAP1 mutations | 8.9% | 271 | 5.3% | 388 | 8.5E−10 |
| MDM2 amplifications | 3.3% | 100 | 4.5% | 326 | .128 |
| MDM4 amplifications | 0.8% | 24 | 0.4% | 30 | .540 |
| APOBEC mutational signature | 6.0% | 182 | 3.9% | 286 | 1.7E−04 |
Fisher’s exact test (p values adjusted with Bonferroni method).
Targetable biomarkers of NSCLC brain metastases (NSCLC-BM) and primary NSCLC (pNSCLC).
| Biomarkers . | NSCLC-BM (n = 3035) . | n . | pNSCLC (n = 7277) . | n . | P-value . |
|---|---|---|---|---|---|
| ALK fusions | 2.7% | 83 | 1.7% | 123 | .020 |
| ROS1 fusions | 0.3% | 10 | 0.5% | 34 | 1 |
| EGFR mutations | 10.9% | 331 | 12.8% | 929 | .191 |
| Exon19del | 4.5% | 137 | 5.5% | 399 | 1 |
| L858R | 3.2% | 97 | 4.2% | 305 | .435 |
| T790M | 0.6% | 18 | 0.9% | 69 | 1 |
| BRAF mutations | 4.3% | 131 | 4.4% | 318 | 1 |
| V600E | 0.9% | 26 | 1.3% | 92 | 1 |
| NTRK fusions | 0.1% | 4 | 0.1% | 6 | 1 |
| METex14 skipping mutations | 1.0% | 31 | 2.3% | 169 | 1.1E−04 |
| RET rearrangements | 0.5% | 16 | 0.7% | 48 | 1 |
| KRAS mutations | 35.7% | 1082 | 29.6% | 2153 | 4.3E−08 |
| G12C | 15.2% | 460 | 11.7% | 853 | 5.9E−05 |
| ERBB2 mutations | 1.9% | 59 | 1.5% | 107 | 1 |
| MET amplifications | 4.4% | 133 | 2.3% | 170 | 1.4E−06 |
| ICPI biomarkers | |||||
| TMB-High | 55.4% | 1680 | 33.6% | 2442 | 1.3E−91 |
| MSI-H | 0.7% | 22 | 0.3% | 22 | .100 |
| CD274 amplifications | 1.5% | 47 | 1.1% | 81 | 1 |
| STK11 mutations | 17.7% | 538 | 11.6% | 847 | 1.5E−14 |
| KEAP1 mutations | 8.9% | 271 | 5.3% | 388 | 8.5E−10 |
| MDM2 amplifications | 3.3% | 100 | 4.5% | 326 | .128 |
| MDM4 amplifications | 0.8% | 24 | 0.4% | 30 | .540 |
| APOBEC mutational signature | 6.0% | 182 | 3.9% | 286 | 1.7E−04 |
| Biomarkers . | NSCLC-BM (n = 3035) . | n . | pNSCLC (n = 7277) . | n . | P-value . |
|---|---|---|---|---|---|
| ALK fusions | 2.7% | 83 | 1.7% | 123 | .020 |
| ROS1 fusions | 0.3% | 10 | 0.5% | 34 | 1 |
| EGFR mutations | 10.9% | 331 | 12.8% | 929 | .191 |
| Exon19del | 4.5% | 137 | 5.5% | 399 | 1 |
| L858R | 3.2% | 97 | 4.2% | 305 | .435 |
| T790M | 0.6% | 18 | 0.9% | 69 | 1 |
| BRAF mutations | 4.3% | 131 | 4.4% | 318 | 1 |
| V600E | 0.9% | 26 | 1.3% | 92 | 1 |
| NTRK fusions | 0.1% | 4 | 0.1% | 6 | 1 |
| METex14 skipping mutations | 1.0% | 31 | 2.3% | 169 | 1.1E−04 |
| RET rearrangements | 0.5% | 16 | 0.7% | 48 | 1 |
| KRAS mutations | 35.7% | 1082 | 29.6% | 2153 | 4.3E−08 |
| G12C | 15.2% | 460 | 11.7% | 853 | 5.9E−05 |
| ERBB2 mutations | 1.9% | 59 | 1.5% | 107 | 1 |
| MET amplifications | 4.4% | 133 | 2.3% | 170 | 1.4E−06 |
| ICPI biomarkers | |||||
| TMB-High | 55.4% | 1680 | 33.6% | 2442 | 1.3E−91 |
| MSI-H | 0.7% | 22 | 0.3% | 22 | .100 |
| CD274 amplifications | 1.5% | 47 | 1.1% | 81 | 1 |
| STK11 mutations | 17.7% | 538 | 11.6% | 847 | 1.5E−14 |
| KEAP1 mutations | 8.9% | 271 | 5.3% | 388 | 8.5E−10 |
| MDM2 amplifications | 3.3% | 100 | 4.5% | 326 | .128 |
| MDM4 amplifications | 0.8% | 24 | 0.4% | 30 | .540 |
| APOBEC mutational signature | 6.0% | 182 | 3.9% | 286 | 1.7E−04 |
Fisher’s exact test (p values adjusted with Bonferroni method).
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
